Title Instructor in Pediatrics Institution Boston Children's Hospital Address Children's Hospital
ID Enders 7
300 Longwood Ave
Boston MA 02115
|
|
Research
The research activities and funding listed below are automatically derived from
NIH ExPORTER and other sources, which might result in incorrect or missing items.
Faculty can
login
to make corrections and additions.
-
75N93019C00044
(David Dowling)
Apr 30, 2022 - Apr 30, 2024
Advancement of TLR7/8 Adjuvant Development
Role Description: This contract supplement supports the development of novel TLR7/8 agonist adjuvants for use in influenza and coronavirus vaccines.
-
TDF2019
(David Dowling)
Jul 30, 2021 - Sep 30, 2023
Boston Children’s Hospital Technology Development Fund
Adjuvant optimization via structure-activity relationship studies
Role Description: This award advances the clinical development of patented adjuvants developed within the Dowling Laboratory.
-
75N93020C00038
(David Dowling)
Oct 1, 2020 - Sep 30, 2025
Development of Vaccines for the Treatment of Opioid Use Disorder
Role Description: This contract is to develop an effective adjuvanted anti-fentanyl vaccine via the induction of anti-fentanyl antibodies that will block the movement of fentanyl from the bloodstream to the brain where it can suppress respiration and cause death. The production of vaccine formulation pilot lots will be completed under good laboratory practice (GLP) to support Investigational New Drug application (IND)-enabling activities in preparation for chemistry, manufacturing, and control (CMC) process-development and current Good Manufacturing Practice (cGMP) production grade formulation scaled up, to support animal and early-stage Phase I/II safety and immunogenicity human clinical trials in adults and/or youths with opioid use disorder (OUD).
Role: Principal Investigator
-
75N93019C00044
(David Dowling)
Apr 30, 2020 - Sep 30, 2022
Vaccine Adjuvant Discovery Program - SARS-CoV-2 Vaccine Development
Role Description: This contract focuses on development of novel adjuvanted SARS-CoV-2 vaccines tailored for use in older humans.
-
75N93019C00044
(David Dowling)
Oct 1, 2019 - Sep 30, 2024
Vaccine Adjuvant Discovery Program
Role Description: This contract is to discover novel adjuvants for influenza and coronavirus vaccines by screening ~100,000 small molecules for activity towards human leukocytes, including newborn and elderly leukocytes, define mechanisms of action, and develop formulated analogs for in vivo murine and ferret studies.
Role: Principal Investigator
-
R21AI137932
(SCOTT, EVAN A)
Nov 8, 2018 - Oct 31, 2020
Leveraging immunostimulatory pathways that enhance BCG vaccination for the rational design of synthetic neonatal vaccine formulations
Role Description: This project characterized mechanisms underlying BCG’s immunostimulation of neonatal immunity, including “trained” immunity, and applied these towards rational design of scalable, synthetic neonatal subunit vaccine formulations.
Role: MPI - David Dowling
Bibliographic
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.